Middleton & Co Inc MA boosted its holdings in Johnson & Johnson (NYSE:JNJ) by 0.5% during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 16,327 shares of the company’s stock after acquiring an additional 75 shares during the quarter. Middleton & Co Inc MA’s holdings in Johnson & Johnson were worth $2,296,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently made changes to their positions in JNJ. Private Capital Advisors Inc. raised its position in Johnson & Johnson by 36.3% during the second quarter. Private Capital Advisors Inc. now owns 9,005 shares of the company’s stock valued at $1,266,000 after purchasing an additional 2,398 shares in the last quarter. Bray Capital Advisors boosted its stake in shares of Johnson & Johnson by 2.2% during the second quarter. Bray Capital Advisors now owns 24,554 shares of the company’s stock valued at $3,453,000 after purchasing an additional 518 shares during the period. Hemenway Trust Co LLC grew its holdings in Johnson & Johnson by 0.9% in the 2nd quarter. Hemenway Trust Co LLC now owns 148,892 shares of the company’s stock worth $20,939,000 after acquiring an additional 1,359 shares during the last quarter. Coho Partners Ltd. grew its stake in shares of Johnson & Johnson by 2.3% in the second quarter. Coho Partners Ltd. now owns 1,334,586 shares of the company’s stock worth $187,683,000 after purchasing an additional 30,473 shares during the last quarter. Finally, Vident Investment Advisory LLC increased its stake in shares of Johnson & Johnson by 25.1% during the second quarter. Vident Investment Advisory LLC now owns 40,948 shares of the company’s stock valued at $5,759,000 after buying an additional 8,228 shares during the period. 68.44% of the stock is currently owned by institutional investors and hedge funds.
In related news, EVP Ashley Mcevoy sold 29,000 shares of the firm’s stock in a transaction on Tuesday, July 28th. The shares were sold at an average price of $147.47, for a total value of $4,276,630.00. Following the completion of the transaction, the executive vice president now directly owns 21,682 shares of the company’s stock, valued at $3,197,444.54. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 0.27% of the stock is owned by corporate insiders.
Shares of JNJ stock opened at $145.76 on Friday. The company’s fifty day simple moving average is $144.04 and its two-hundred day simple moving average is $144.14. Johnson & Johnson has a 52 week low of $109.16 and a 52 week high of $157.00. The stock has a market cap of $383.76 billion, a P/E ratio of 21.31, a PEG ratio of 3.23 and a beta of 0.69. The company has a quick ratio of 1.05, a current ratio of 1.25 and a debt-to-equity ratio of 0.40.
Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Thursday, July 16th. The company reported $1.67 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.50 by $0.17. Johnson & Johnson had a return on equity of 35.21% and a net margin of 22.69%. The firm had revenue of $18.34 billion for the quarter, compared to analysts’ expectations of $17.73 billion. During the same period in the previous year, the firm posted $2.58 earnings per share. The business’s revenue was down 10.8% compared to the same quarter last year. On average, analysts anticipate that Johnson & Johnson will post 7.85 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th will be issued a dividend of $1.01 per share. The ex-dividend date is Monday, August 24th. This represents a $4.04 annualized dividend and a dividend yield of 2.77%. Johnson & Johnson’s dividend payout ratio (DPR) is 46.54%.
A number of equities analysts have issued reports on JNJ shares. Citigroup increased their price objective on Johnson & Johnson from $165.00 to $170.00 and gave the stock a “buy” rating in a report on Friday, July 17th. Zacks Investment Research lowered shares of Johnson & Johnson from a “hold” rating to a “sell” rating and set a $150.00 price target for the company. in a research note on Tuesday, July 7th. Stifel Nicolaus raised their target price on shares of Johnson & Johnson from $140.00 to $155.00 and gave the stock a “hold” rating in a report on Wednesday, April 15th. Independent Research upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and boosted their target price for the company from $161.00 to $164.00 in a research note on Monday, July 20th. Finally, SVB Leerink restated an “outperform” rating on shares of Johnson & Johnson in a research note on Wednesday, July 15th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and twelve have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $163.38.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
See Also: Accumulation/Distribution
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.